Cancer Genetics, a global partner for biopharma companies
Posted on: Thursday, May 28th, 2015
Panna Sharma, CEO of Cancer Genetics, Inc. speaks about Cancer genetics, a global partner for biopharma companies
Globally cancer is increasing significantly and with that increase comes more complexity to understand and diagnose cancers. In countries like India or China, they expect a 5 fold increase of newly diagnosed cancers, and also significant increase of cost associated with care.
As Biotech & Pharma companies expand their clinical trials globally, there is a significant need for them to have the same global standards, the same quality results and same the data across the globe, and across multiple sites.
Biotech & Pharma companies are facing the duel challenge of decreasing the cost of their clinical trials while they need to improve the speed at which they are able to get to approval. With facilities in India & China, Cancer Genetics can ensure that all labs maintain the same level of results, the same level quality, and follow the same SOPs.
In both these countries, it is not only essential that we serve the biopharma companies, but equally essential that the patients in these countries get access to the same quality genomic tests and same standards in data that our test provide.
Cancer Genetics is expanding its footprint. Cancer Genetics is empowering the personalization of cancer treatment globally.